Form 4: Coya Therapeutics Director Acquires Stock Options

A Coya Therapeutics director, Ann Lee, acquired 5,000 stock options on January 1, 2025, according to a recent SEC filing.

Summary

• Ann Lee, a director at Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.
• The options have an exercise price of $5.73 per share.
• The options vest 100% on the first anniversary of the grant date, which is January 1, 2026.
• The options expire on January 1, 2035.
• The filing indicates that the options were acquired directly by the director.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to stock option grants, which is neither particularly positive nor negative. It indicates standard corporate governance practices.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC filing related to insider transactions, which is common for publicly traded companies.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of one year is also a typical arrangement to align the director's interests with the long-term performance of the company.
• The exercise price of $5.73 is a specific value for this grant and would need to be compared to other grants to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, Coya Therapeutics, director, equity